Kiniksa Pharmaceuticals, Ltd. (KNSA) Q2 FY26 Earnings Call

Koniksa reported $243.6 million in Q2 Arcalist revenue and raised full-year guidance to $980 to $995 million.

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Call date2026-07-28
Length38 minutes
EPS$0.30
EPS consensus$0.30
Revenue$214.3M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q4 FY25

All KNSA earnings ยท Back to KNSA overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.